Suchergebnisse - "Rimassa, Lorenza"

PubPharm (370)

81

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8 : a retrospective analysis of the CELESTIAL randomised controlled trial

enthalten in: BMC cancer | 2022

von El-Khoueiry, A. | Meyer, T. | Cheng, A. | +5

82

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

enthalten in: BMC cancer | 2022

von El-Khoueiry, A. | Meyer, T. | Cheng, A. | +5

83

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

enthalten in: BMC cancer | 2022

von El-Khoueiry, A. | Meyer, T. | Cheng, A. | +5

84

Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma : shedding light on the preclinical rationale and clinical trials

enthalten in: Expert opinion on investigational drugs | 2022

von Cammarota, A. | Zanuso, V. | D'Alessio, A. | +3

85

The dual checkpoint blockade in unresectable hepatocellular carcinoma : opportunities emerging in clinical trials

enthalten in: Expert opinion on investigational drugs | 2022

von Cammarota, A. | Zanuso, V. | D'Alessio, A. | +4

86

Correction to : Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma

enthalten in: Clinical drug investigation | 2022

von Ryoo, B. | Palmer, D. | Park, S. | +6

ErratumFor: Clin Drug Investig. 2021 Sep;41(9):795-808. - PMID 34351608

87

Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Personeni, N. | Rimassa, L.

CommentOn: Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218. - PMID 35065057

88

Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma

enthalten in: Clinical drug investigation | 2022

von Ryoo, B. | Palmer, D. | Park, S. | +6

89

Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma

enthalten in: Clinical drug investigation | 2022

von Ryoo, B. | Palmer, D. | Park, S. | +6

90

Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma

enthalten in: Clinical drug investigation | 2022

von Ryoo, B. | Palmer, D. | Park, S. | +6